High-avidity autoreactive CD4+ T cells induce host CTL, overcome tregs and mediate tumor destruction

Journal of Immunotherapy

Volumn 32, Issue 7, 2009, Pages 677-688

  Brandmaier, Andrew G ^a   Leitner, Wolfgang W ^b   Ha, Sung P ^a   Sidney, John ^c   Restifo, Nicholas P ^b   Touloukian, Christopher E ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

CD4 T cells; Knockout mice; Melanoma; Tolerance suppression anergy; Tumor immunity

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FREUND ADJUVANT; GAMMA INTERFERON; GENOMIC DNA; HLA DR ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PC 61; OVALBUMIN; RECOMBINANT TYROSINASE RELATED PROTEIN 1; TRANSCRIPTION FACTOR FOXP3; TYROSINASE RELATED PROTEIN 1; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; AUTOREACTIVE CD4+ T LYMPHOCYTE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL EXPANSION; CELL FUNCTION; CELL INTERACTION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOREACTIVITY; INTRAVENOUS ADMINISTRATION; KNOCKOUT MOUSE; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SEQUENCE ANALYSIS; T CELL DEPLETION; TRANSGENIC MOUSE;

ANIMALS; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HLA-DR ANTIGENS; HLA-DR4 ANTIGEN; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OXIDOREDUCTASES; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 68449088814     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181ab1824     Document Type: Article

References (77)

1. Boon T, Coulie PG, Van Den Eynde BJ, et al. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24: 175-208.
2. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
3. Peggs KS, Segal NH, Allison JP. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell. 2007;12:192-199.
4. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
5. Lizee G, Cantu MA, Hwu P. Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin Cancer Res. 2007; 13:5250-5255.
6. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51-81.
7. + T cells are required for the maintenance, not programming, of memory CD8 + T cells after acute infection. Nat Immunol. 2004;5:927-933.
8. + memory T cells. Immunol Rev. 2006;211: 146-153.
9. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188:2357-2368.
10. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281-355.
11. Dighe AS, Richards E, Old LJ, et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994;1:447-456.
12. Williamson BD, Carswell EA, Rubin BY, et al. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A. 1983;80:5397-5401.
13. Coughlin CM, Salhany KE, Gee MS, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity. 1998;9:25-34.
14. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med. 1997;186: 2057-2062.
15. + T cell reactivity to a model tumor antigen. J Immunol. 2000;164:562-565.
16. Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 2007;109:5346-5354.
17. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112:362-373.
18. Armstrong CA, Botella R, Galloway TH, et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res. 1996;56:2191-2198.
19. Xu Y, Setaluri V, Takechi Y, et al. Sorting and secretion of a melanosome membrane protein, gp75/TRP1. J Invest Dermatol. 1997;109:788-795.
20. Murisier F, Beermann F. Genetics of pigment cells: lessons from the tyrosinase gene family. Histol Histopathol. 2006;21: 567-578.
21. Touloukian CE, Leitner WW, Robbins PF, et al. Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Res. 2002;62: 5144-5147.
22. Overwijk WW, Lee DS, Surman DR, et al. Vaccination with a recombinant vaccinia virus encoding a self antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A. 1999;96:2982-2987.
23. Bowne WB, Srinivasan R, Wolchok JD, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med. 1999;190:1717-1722.
24. Leitner WW, Hwang LN, deVeer MJ, et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med. 2003;9:33-39.
25. Javerzat S, Jackson IJ. White-based brown (Tyrp1B-w) is a dominant mutation causing reduced hair pigmentation owing to a chromosomal inversion. Mamm Genome. 1998;9:469-471.
26. Yu Z, Theoret MR, Touloukian CE, et al. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest. 2004;114:551-559.
27. Colella TA, Bullock TN, Russell LB, et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med. 2000;191: 1221-1232.
28. Touloukian CE, Leitner WW, Schnur RE, et al. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. J Immunol. 2003;170:1579-1585.
29. Jackson IJ, Chambers D, Rinchik EM, et al. Characterization of TRP-1 mRNA levels in dominant and recessive mutations at the mouse brown (b) locus. Genetics. 1990;126:451-459.
30. Smyth IM, Wilming L, Lee AW, et al. Genomic anatomy of the Tyrpl (brown) deletion complex. Proc Natl Acad Sci USA. 2006;103:3704-3709.
31. Wakeland E, Morel L, Achey K, et al. Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol Today. 1997;18:472-477.
32. Ito K, Bian HJ, Molina M, et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med. 1996;183: 2635-2644.
33. Kurts C, Heath WR, Carbone FR, et al. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med. 1996;184:923-930.
34. Barnden MJ, Allison J, Heath WR, et al. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol. 1998;76:34-40.
35. Touloukian CE, Leitner WW, Topalian SL, et al. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol. 2000;164:3535-3542.
36. Touloukian CE, Leitner WW, Robbins PF, et al. Mining the melanosome for tumor vaccine targets: P. polypeptide is a novel tumor-associated antigen. Cancer Res. 2001;61: 8100-8104.
37. Jackson IJ. Homologous pigmentation mutations in human, mouse and other model organisms. Hum Mol Genet. 1997;6: 1613-1624.
38. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Thl7 lineage. Curr Opin Immunol. 2006;18:349-356.
39. + T cells. J Exp Med. 2003; 198:569-580.
40. + regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004;20:107-118.
41. + suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2:389-400.
42. Baecher-Allan C, Anderson DE. Immune regulation in tumorbearing hosts. Curr Opin Immunol. 2006;18:214-219.
43. Sutmuller RP, van Duivenvoorde LM, van EA, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194:823-832.
44. + regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol. 2006;176: 1750-1758.
45. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic selftolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303-310.
46. Matsushita N, Pilon-Thomas SA, Martin LM, et al. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods. 2008;333:167-179.
47. Kleindienst P, Wiethe C, Lutz MB, et al. Simultaneous induction of CD4 T cell tolerance and CD8 T cell immunity by semimature dendritic cells. J Immunol. 2005;174:3941-3947.
48. Rosenberg SA. Development of effective immunotherapy for the treatment of patients with cancer. J Am Coll Surg. 2004; 198:685-696.
49. + T cell responses in antitumor immunity. Curr Opin Immunol. 1998;10:588-594.
50. Gerloni M, Zanetti M. CD4 T cells in tumor immunity. Springer Semin Immunopathol. 2005;27:37-48.
51. Ossendorp F, Mengede E, Camps M, et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med. 1998;187:693-702.
52. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest. 2001; 107: 477-484.
53. Langlade-Demoyen P, Garcia-Pons F, Castiglioni P, et al. Role of T cell help and endoplasmic reticulum targeting in protective CTL response against influenza virus. Eur J Immunol. 2003; 33:720-728.
54. + T cells. J Immunol. 1999;162:696-703.
55. Schoenberger SP, Toes RE, Van der, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
56. Ndejembi MP, Teijaro JR, Patke DS, et al. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol. 2006;177:7698-7706.
57. Soroosh P, Ine S, Sugamura K, et al. OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. J Immunol. 2006;176:5975-5987.
58. + T-helper and a T-killer cell. Nature. 1998;393:474-478.
59. + regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci. 2007;98:416-423.
60. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591-2601.
61. Bai A, Higham E, Eisen HN, et al. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci USA. 2008;105:13003-13008.
62. +. J Immunol. 2004;172: 5213-5221.
63. + regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol. 2000;30:1538-1543.
64. + T cells. Adv Immunol. 2003;81:331-371.
65. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-687.
66. Hildeman DA, Zhu Y, Mitchell TC, et al. Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol. 2002;14:354-359.
67. Spiotto MT, Fu YX, Schreiber H. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr Opin Immunol. 2003;15:725-730.
68. Magalhaes DA, Silveira EL, Junta CM, et al. Promiscuous gene expression in the thymus: the root of central tolerance. Clin Dev Immunol. 2006;13:81-99.
69. Kyewski B, Derbinski J. Self-representation in the thymus: an extended view. Nat Rev Immunol. 2004;4:688-698.
70. Sospedra M, Ferrer-Francesch X, Dominguez O, et al. Transcription of a broad range of self-antigens in human thymus suggests a role for central mechanisms in tolerance toward peripheral antigens. J Immunol. 1998;161:5918-5929.
71. Gallegos AM, Bevan MJ. Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J Exp Med. 2004;200:1039-1049.
72. Anderson MS, Venanzi ES, Chen Z, et al. The cellular mechanism of Aire control of T cell tolerance. Immunity. 2005; 23:227-239.
73. + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity. 2005;22:117-129.
74. Cohen CJ, Zheng Z, Bray R, et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol. 2005;175:5799-5808.
75. Barger BO, Acton RT, Soong SJ, et al. Increase of HLA-DR4 in melanoma patients from Alabama. Cancer Res. 1982;42: 4276-4279.
76. Marincola FM, Shamamian P, Rivoltini L, et al. HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol. 1995;18: 242-252.
77. Southwood S, Sidney J, Kondo A, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol. 1998;160:3363-3373.